Company intelligence / Profile preview
LamKap Bio Group
Pfäffikon, Schwyz, Switzerlandlamkapbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
LamKap Bio Group develops bispecific and multispecific antibodies that redirect the patient’s immune system—specifically macrophages, T-cells, and NK cells—to target malignant tumors. The company leverages a team with extensive experience in pharma and academia to create novel immunotherapies for cancer. No published late-stage clinical results are available as of now.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodiesMultispecific antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Lonza
Beyond the preview
Go deeper on LamKap Bio Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LamKap Bio Group.